Investor Objections Can't Halt Amgen's $1.2B Micromet Buy
A Delaware judge refused to block Amgen Inc.'s $1.16 billion purchase of cancer drug specialist Micromet Inc. on Wednesday, rejecting claims in a class action that the offer was deceptive and...To view the full article, register now.
Already a subscriber? Click here to view full article